Findings from a nationally representative US survey show that a substantial minority of people with diabetes ration their use of insulin because of issues with affordability.
The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.
Findings from the phase 2 ARCADIA trial suggest that treatment with a glucokinase activator may aid the recovery of people with diabetes who are hospitalized with severe COVID-19.
The disruption of routine diabetes care during the pandemic may have resulted in an increased risk for mortality from causes not linked to COVID-19, research suggests.
The proven cardiovascular benefits of SGLT2 inhibitors has not led doctors to prioritize their use in people at high risk, show findings from UK general practice.